SYN023
Phase 2Biologic
SYN023 is one of 2 biologic programs targeting Rabies. It is currently in Phase 2.
1
Indications
4
Total Trials
0
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
2 competitors in Rabies
#DrugCompanyPhaseTrials
1Rabies Vaccine
NovartisPhase 2
SYN023
SSynermore Biologics (Suzhou) Co., Ltd.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SYN023. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details